Skip to main content

Table 2 Number and percentage of cases according to components of therapy in patients with KD at the NUNH Hospital between the 21st Nationwide survey (2009–10) and the second cohort (high-dose IVIG)

From: Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study

  21stNationwide survey (2009–10) Second cohort (2010–12) p-value
Total 23,730 100.0 112 100.0  
Dosage of IVIG Cases % Cases %  
2 g/kg 17,547 74.0 85 75.9 0.75
1 g/kg/day × 2 d 2,803 11.8 5 4.5 0.01
400 mg/kg/day × 5 d 20 0.08 4 3.6 0.001
Various dosages of IVIG 868 3.65 0 0 0.04
Aspirin alone (no IVIG) 2,492 10.5 18 16.1 0.06
Dalteparin 0 0 112 100.0  
Age (months) -* 19 (0–66)  
Male sex 13,515 (57.0%) 59 (52.7%) 0.39
  1. Dalteparin was administered until the patient was afebrile, clinically improving, and/or showed a CRP < 1.0 mg/dL.
  2. Data are median (range), n (%).
  3. *The prevalence was highest among children aged 6–11 months [3].